OakChart

Monopar Therapeutics Inc

MNPRHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

71.73-0.05 (-0.07%)
2026-11-11 23:26 CET
Market cap
481.80 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-17.84 USD m
Free cash flow, TTM
-12.18 USD m
EPS diluted, TTM
-2.34
P/E
-
Compare

Price

MNPR against its 20, 50 and 200-day averages
2050200beat
60.0080.00100.00120.00264K529KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MNPRclose 71.7320-day 71.2650-day 84.40200-day 77.2271.7352w high52w low

42.5% under the 52-week high of 124.82 on 6 Aug 2026. 52-week low 50.07 on 29 Apr 2026. Last 15 sessions, 16.4% high to low

Volume 0.99× normal · the line is the 50-bar volume average

Profile

MNPR
52-week range, 29% of the way up
50.07124.82

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

IndexRUT
Employees22
IPODec 19, 2019
Beta1.62
ATR, 14d4.30
Rel volume0.99
Short float28.01%
Insider own41.33%
Inst own76.97%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap481.46M
Enterprise Value347.27M
Income-17.84M
Sales0.00M
Book/sh19.50
Cash/sh20.01
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees22
IPODec 19, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.68
P/C3.58
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio33.56
Current Ratio33.56
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.34
EPS next Y-2.46
EPS next Q-0.82
EPS this Y-60.91%
EPS next Y17.27%
EPS next 5Y-0.20%
EPS past 3/5Y23.50% 8.44%
Sales past 3/5Y- -
EPS Y/Y TTM29.73%
Sales Y/Y TTM-
EPS Q/Q-77.41%
Sales Q/Q-
EarningsAug 12 BMO
EPS/Sales Surpr.4.19% -

Ownership

Insider Own41.33%
Insider Trans-1.84%
Inst Own76.97%
Inst Trans-3.18%
ROA-18.90%
ROE-19.50%
ROIC-13.63%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.66%
SMA50-15.01%
SMA200-7.11%
Trades-

Technical

Shs Outstand6.71M
Shs Float3.94M
Short Float28.01%
Short Ratio6.91
Short Interest1.10M
52W High124.82 -42.53%
52W Low50.07 43.26%
Volatility7.66% 5.60%
ATR (14)4.30
RSI (14)44.58
Beta1.62
Rel Volume0.99
Avg Volume159.66K
Volume157,470

Performance

Perf Week-1.48%
Perf Month-0.49%
Perf Quarter-35.03%
Perf Half Y16.75%
Perf YTD9.85%
Perf Year-14.02%
Perf 3Y3790.97%
Perf 5Y186.35%
Perf 10Y-
Recom1.30
Target Price129.91
Prev Close71.78
Price71.73
Change %-0.07%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Aug 13, 2026DowngradeCCantor FitzgeraldOverweight → Neutral$119+65.9%
Jan 09, 2026InitiatedMMorgan StanleyOverweight$115+60.3%
Nov 14, 2025DowngradeRRaymond JamesStrong Buy → Outperform
Nov 10, 2025InitiatedLLeerink PartnersOutperform$115+60.3%
Oct 13, 2025InitiatedBBarclaysOverweight$125+74.3%
Sep 09, 2025InitiatedBBTIG ResearchBuy$87+21.3%
Sep 03, 2025InitiatedRRaymond JamesStrong Buy$80+11.5%
Sep 03, 2025InitiatedOOppenheimerOutperform$77+7.3%
Aug 26, 2025ResumedHH.C. WainwrightBuy$70-2.4%
Jul 07, 2025InitiatedCCantor FitzgeraldOverweight$74+3.2%

Peers

Mkt cap
TickerCompanyMkt cap
ZVRAZevra Therapeutics Inc705.13M
AKTSAktis Oncology Inc947.76M
TLXTelix Pharmaceuticals Ltd ADR3.31B
RAREUltragenyx Pharmaceutical Inc1.70B
RZLTRezolute Inc393.69M
SPRBSpruce Biosciences Inc132.78M
MIRMMirum Pharmaceuticals Inc6.18B
RADXRadiopharm Theranostics Ltd ADR12.87M
ATNMActinium Pharmaceuticals Inc49.99M
CLRBCellectar Biosciences Inc11.44M

Insider trading

latest 14 of 23
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Anderson RaymondDirectorNov 02 '26Option Exercise30.003,14294,2588,515Nov 04 08:15 PM
Anderson RaymondDirectorNov 02 '26Sale68.353,142214,7465,373Nov 04 08:15 PM
Tsuchimoto Kim RDirectorNov 04 '26Option Exercise18.742,89154,1702,891Nov 04 08:15 PM
Tsuchimoto Kim RDirectorNov 02 '26Option Exercise30.001,19935,9701,199Nov 04 08:15 PM
Tsuchimoto Kim RDirectorNov 04 '26Sale71.262,891206,0120Nov 04 08:15 PM
Tsuchimoto Kim RDirectorNov 02 '26Sale70.101,19984,0500Nov 04 08:15 PM
STARR CHRISTOPHER MDirectorOct 01 '26Option Exercise0.018,4004213,573Oct 05 05:43 PM
STARR CHRISTOPHER MDirectorOct 01 '26Sale78.508,400659,3875,173Oct 05 05:43 PM
CHRISTOPHER STARRDirectorOct 01 '26Proposed Sale79.6716,8001,338,456Oct 01 04:37 PM
Robinson ChandlerChief Executive OfficerSep 24 '26Option Exercise21.7429,056631,680128,323Sep 28 08:47 PM
Robinson ChandlerChief Executive OfficerSep 24 '26Sale88.0029,0562,556,85199,267Sep 28 08:47 PM
CHANDLER ROBINSONDirectorSep 24 '26Proposed Sale89.3829,0562,597,025Sep 24 04:40 PM
RIOUX PATRICEActing Chief Medical OfficerAug 26 '26Option Exercise0.011,38075,066Aug 27 07:29 PM
RIOUX PATRICEActing Chief Medical OfficerAug 26 '26Sale111.2611115,065Aug 27 07:29 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
LABUDirexion Daily S&P Biotech Bull 3X ETFAUM: 583.37M

News

latest 14 of 200
  • Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD - The Liver Meeting 2026 (GlobeNewswire)
  • Monopar to Present at AASLD - The Liver Meeting 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data (GlobeNewswire) -5.75%
  • Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - The Liver Meeting 2026 (GlobeNewswire)
  • Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease (GlobeNewswire)
  • Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team (GlobeNewswire)
  • Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease (GlobeNewswire)
  • Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease (GlobeNewswire) +7.85%
  • Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 (GlobeNewswire)
  • Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease (GlobeNewswire) +17.66%
  • Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 (GlobeNewswire)
  • Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
  • Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-0.620-0.647-0.6200.000.0011
2026Q12026-05-14-0.460-0.807-0.4560.000.0013
2025Q42026-03-27-0.640-0.481-0.7770.000.0013
2025Q32025-11-13-0.480-0.417-0.4830.000.0013
2025Q22025-08-12-0.350-0.458-0.3510.000.006
2025Q12025-05-13-0.380-0.520-0.3760.000.004
2024Q42025-03-31-2.740-0.378-2.2300.000.005
2024Q32024-11-08-0.370-0.995-0.3710.000.004
2024Q22024-08-09-0.500-0.500-0.4900.000.003
2024Q12024-05-09-0.500-0.725-0.5140.000.002
2023Q42024-03-29-0.625-0.817-0.6090.000.003
2023Q32023-11-10-0.700-0.767-0.6920.000.003
2023Q22023-08-10-0.800-0.920-0.8200.000.005
2023Q12023-05-11-0.950-1.110-0.9290.000.005
2022Q42023-03-23-1.150-1.025-1.1190.000.006
2022Q32022-11-10-0.950-1.084-0.9410.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.250-1.950-1.9950.000.00
2020FY-2.900-2.863-2.8770.000.00
2021FY-3.650-3.560-3.6490.000.00
2022FY-4.150-4.134-4.1340.000.00
2023FY-3.050--3.0390.00-
2024FY-4.110-1.376-4.1120.000.00
2025FY-1.850-1.680-1.8500.000.00
2026FY--2.977--0.00
2027FY--2.463--27.90
2028FY--1.861--84.70
2029FY-0.626--168.26
2030FY-4.839--282.47

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-078000.000.000.00
2026Q3S2026-08-229000.000.000.00
2026Q3S2026-08-1210000.000.000.00
2026Q3S2026-07-0510000.000.000.00
2026Q3S2026-05-1411000.000.000.00
2026Q3S2026-05-1311000.000.000.00
2026Q3S2026-04-1710000.000.000.00
2026Q3S2026-03-279000.000.000.00
2026Q3S2026-02-157000.000.000.00
2026Q3S2026-01-018000.000.000.00
2026Q3S2025-11-139000.000.000.00
2026Q3S2025-11-119000.000.000.00
2026Q3S2025-11-109000.000.000.00
2026Q3S2025-11-099000.000.000.00

Estimate history

EPS, annual-7.818-1.524-1.995-2.877-3.649-4.134-3.039-4.112-1.851-2.3378
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.49-0.371-2.23-0.376-0.351-0.483-0.777-0.456-0.622
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual2.1182.1182.1182.2912.522.5892.9816.1036.6926.712
Period201720182019202020212022202320242025MRQ
Shares, quarterly3.523.5256.1036.1156.1276.6636.6926.6996.712
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other22.1216.7016.168.8310.549.136.514.323.33
Research and Development14.789.9013.015.607.596.494.071.971.77
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-22.12-16.70-16.16-8.83-10.54-9.13-6.51-4.32-3.33
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.00-0.12-0.00
Net Income Before Taxes-17.84-13.72-15.59-8.40-10.51-9.10-6.30-4.22-3.23
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-17.84-13.72-15.59-8.40-10.52-9.10-6.30-4.22-3.23
Net Income From Continuing Operations-17.84-13.72-15.59-8.40-10.52-9.10-6.30-4.22-3.23
Net Income-17.84-13.72-15.59-8.40-10.52-9.10-6.30-4.22-3.23
EPS (Recurring)-2.09-1.85-4.11-3.04-4.13-3.65-2.92-2.00-1.52
EPS (Basic, Before Extraordinaries)-2.34-1.85-4.11-3.04-4.13-3.65-2.88-2.00-1.52
EPS (Diluted)-2.34-1.85-4.11-3.04-4.13-3.65-2.88-2.00-1.52
EBITDA-22.12-16.70-16.16-8.83-10.54-9.13-6.51-4.32-3.33
Non-Operating Income (Expense)4.272.990.580.430.020.020.080.100.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.324.841.141.901.301.431.250.930.40
Shares Outstanding6.716.696.102.982.592.522.292.122.12
Market Capitalization481.80481.80133.684.8330.4740.4470.10175.75196.40

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other6.645.236.164.093.233.2211.071.57
Research and Development4.773.493.942.591.731.649.920.98
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.64-5.23-6.16-4.09-3.23-3.22-11.07-1.57
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-5.31-3.89-5.20-3.44-2.45-2.62-10.93-1.30
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.31-3.89-5.20-3.44-2.45-2.62-10.93-1.30
Net Income From Continuing Operations-5.31-3.89-5.20-3.44-2.45-2.62-10.93-1.30
Net Income-5.31-3.89-5.20-3.44-2.45-2.62-10.93-1.30
EPS (Recurring)-0.62-0.46-0.78-0.48-0.35-0.38-2.23-0.37
EPS (Basic, Before Extraordinaries)-0.62-0.46-0.78-0.48-0.35-0.38-2.23-0.37
EPS (Diluted)-0.62-0.46-0.78-0.48-0.35-0.38-2.23-0.37
EBITDA-6.64-5.23-6.16-4.09-3.23-3.22-11.07-1.57
Non-Operating Income (Expense)1.331.330.950.660.780.600.150.27
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.431.691.101.101.241.360.280.20
Shares Outstanding6.716.706.696.666.136.126.103.53
Market Capitalization481.80366.66436.37503.90218.80222.19133.6823.73

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments140.4060.217.2713.1220.3016.7413.216.898.98
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.060.080.070.050.220.060.010.010.15
Total Current Assets140.4660.297.3313.1720.5216.8013.226.919.13
Net Property, Plant & Equipment0.250.000.010.060.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.80
Intangible Assets0.000.000.000.000.00--0.000.00
Other Assets0.000.000.000.000.000.070.130.410.00
Total Assets140.7260.297.3513.2320.5216.8713.357.329.93
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.050.000.000.000.000.00
Accounts Payable2.742.251.763.081.581.180.720.400.31
Other Current Liabilities0.003.000.00-0.000.000.000.000.000.00
Total Current Liabilities2.745.251.763.131.581.180.720.400.31
Long Term Debt0.150.000.000.010.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities2.895.251.763.141.581.180.720.400.31
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity137.8355.045.5910.0918.9415.6912.636.929.62
Total Shareholders Equity137.8355.045.5910.0918.9415.6912.636.929.62
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity137.8355.045.5910.0918.9415.6912.636.929.62
Total Liabilities & Stockholders Equity140.7260.297.3513.2320.5216.8713.357.329.93
Book Value Per Share20.609.021.873.907.526.855.963.274.54
Tangible Book Value Per Share20.609.021.873.907.526.855.963.274.54
Full-Time Employees221610121010755
Price to Book Ratio3.6815.680.732.442.134.4713.9242.47-
Return on Assets-13.65-46.09-81.69-62.32-48.69-41.72-40.88-37.43-258.13
Return on Equity-14.22-51.42-107.19-72.44-52.57-44.52-43.23-39.04-265.93
Return on Invested Capital-9.94-28.32-150.37-104.14-48.06-40.18-33.46-46.66-172.10
Quick Ratio51.3511.474.174.2112.9814.2818.2517.2929.28
Current Ratio51.3511.474.174.2112.9814.2818.2517.2929.28

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-17.84-13.72-15.59-8.40-10.52-9.10-6.30-4.22-3.23
Other Funds (Non Cash)3.104.125.691.901.641.471.201.010.53
Funds from Operations-14.74-9.60-9.89-6.50-8.87-7.64-5.11-3.21-2.70
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.56-2.613.49-1.351.650.320.440.200.02
Cash from Operating Activities-12.18-12.20-6.40-7.86-7.23-7.32-4.66-3.02-2.68
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-65.78-63.45-14.344.93-4.920.000.000.000.00
Purchase of Investments-172.44-87.15-15.32-7.88-4.920.000.000.000.00
Sale Or Maturity of Investments106.6523.700.9912.810.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-65.78-63.45-14.344.93-4.920.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock92.6992.7159.402.070.1110.948.069.35-0.21
Repurchase of Common Pref Stock-35.00-35.000.000.000.000.000.000.000.00
Sale of Common Pref Stock127.69127.7159.402.070.1110.948.069.35-0.21
Proceedsfrom Stock Options127.14127.1459.402.070.1110.938.069.24-0.21
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.120.000.00
Change in Long Term Debt0.000.000.000.000.000.000.120.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.120.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-1.53-1.13-0.10-0.05-0.08-0.060.000.000.00
Other Financing Activities Uses-1.53-1.13-0.10-0.05-0.08-0.060.000.000.00
Cash from Financing Activities91.1691.5759.292.030.0310.888.189.35-0.21
Exchange Rate Effect0.060.100.00-0.02-0.000.000.00-0.01-0.00
Net Change in Cash13.2616.0238.55-0.92-12.123.573.526.32-2.89
Free Cash Flow-12.18-12.20-6.40-7.86-7.23-7.32-4.66-3.02-2.68
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments134.30137.49140.40143.6853.2554.55
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.460.250.060.410.500.52
Total Current Assets134.76137.74140.46144.0953.7555.08
Net Property, Plant & Equipment0.220.240.250.110.120.01
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets134.98137.98140.72144.2053.8755.09
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.030.00
Accounts Payable4.022.462.742.571.551.49
Other Current Liabilities0.000.000.000.000.000.00
Total Current Liabilities4.022.462.742.571.581.49
Long Term Debt0.110.130.150.070.080.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.122.592.892.641.661.49
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity130.85135.39137.83141.5652.2053.59
Total Shareholders Equity130.85135.39137.83141.5652.2053.59
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity130.85135.39137.83141.5652.2053.59
Total Liabilities & Stockholders Equity134.98137.98140.72144.2053.8755.09
Book Value Per Share19.5020.2120.6021.258.528.76
Tangible Book Value Per Share19.5020.2120.6021.258.528.76
Full-Time Employees--22---
Price to Book Ratio3.682.663.079.594.084.04
Return on Assets-18.90-15.52-13.65-25.88-56.71-51.78
Return on Equity-19.50-15.86-14.22-26.54-59.38-54.27
Return on Invested Capital-4.06-2.87-3.77-2.43-4.69-4.90
Quick Ratio33.5656.0451.3556.1033.9436.92
Current Ratio33.5656.0451.3556.1033.9436.92

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-5.31-3.89-5.20-3.44-2.45-2.62
Other Funds (Non Cash)0.720.890.391.101.281.36
Funds from Operations-4.59-3.00-4.81-2.34-1.17-1.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.35-0.471.440.250.10-4.39
Cash from Operating Activities-3.25-3.47-3.37-2.09-1.08-5.66
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments4.12-5.58-62.19-2.131.19-0.33
Purchase of Investments-47.58-40.84-78.29-5.73-1.21-1.93
Sale Or Maturity of Investments51.7035.2516.103.602.401.60
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities4.12-5.58-62.19-2.131.19-0.33
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.010.00-0.0992.770.000.02
Repurchase of Common Pref Stock0.000.000.00-35.000.000.00
Sale of Common Pref Stock0.010.00-0.09127.770.000.02
Proceedsfrom Stock Options0.000.00-0.63127.770.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.65-0.20-0.30-0.38-0.32-0.13
Other Financing Activities Uses-0.65-0.20-0.30-0.38-0.32-0.13
Cash from Financing Activities-0.65-0.20-0.3892.39-0.32-0.12
Exchange Rate Effect-0.01-0.030.100.00-0.00-0.00
Net Change in Cash0.21-9.29-65.8488.18-0.21-6.10
Free Cash Flow-3.25-3.47-3.37-2.09-1.08-5.66

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3028.01%1.1M3.9M176.26K
2026-10-1528.65%1.1M3.9M206.23K
2026-09-3027.57%1.1M3.9M218.11K
2026-09-1521.37%0.8M4.0M217.91K
2026-08-3121.64%0.9M3.9M217.38K
2026-08-1422.52%0.9M3.9M216.20K
2026-07-3125.60%1.1M4.2M207.46K
2026-07-1532.70%1.4M4.2M178.02K
2026-06-3036.71%1.5M4.1M170.73K
2026-06-1537.64%1.6M4.1M177.28K
2026-05-2938.15%1.6M4.1M183.55K
2026-05-1537.90%1.6M4.1M183.75K
2026-04-3038.49%1.7M4.3M199.76K
2026-04-1539.71%1.7M4.3M226.73K
2026-03-3138.28%1.7M4.4M248.14K
2026-03-1337.58%1.7M4.4M270.46K
2026-02-2736.14%1.6M4.4M271.77K
2026-02-1334.24%1.5M4.4M266.10K
2026-01-3029.85%1.4M4.5M247.33K
2026-01-1528.18%1.3M4.5M208.75K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-10-27SCHEDULE 13GSEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-284/A2026-08-26SEC
2026-08-284/A2026-08-25SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-12SCHEDULE 13G/ASEC
2026-07-22S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-07-22S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-07-22S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-07-22S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-07-22S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-228-KCurrent report2026-07-22SEC
2026-07-10144/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100504.81K3
2026-1000659.39K1
2026-09002.56M1
2026-0800806.87K3
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12104.93K1343.89K1
2025-110000

Institutional holders

Manager% owned
Jupiter Topco LLC19.59%
RA CAPITAL MANAGEMENT, L.P.9.96%
BlackRock, Inc.5.21%
DEERFIELD MANAGEMENT COMPANY, L.P.4.83%
Saturn V Capital Management LP4.66%
Siren, L.L.C.4.03%
ADAR1 Capital Management, LLC3.25%
Polar Capital Holdings Plc3.20%
VANGUARD CAPITAL MANAGEMENT LLC3.13%
ADAGE CAPITAL PARTNERS GP, L.L.C.3.12%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.39%
iShares Russell 2000 ETF1.77%
Fidelity Small Cap Index Fund0.74%
VANGUARD EXTENDED MARKET INDEX FUND0.66%
iShares Russell 2000 Value ETF0.47%
VANGUARD RUSSELL 2000 INDEX FUND0.38%
Neuberger Small Cap Growth Fund0.38%
BNY Mellon Small/Mid Cap Growth Fund0.36%
Fidelity Extended Market Index Fund0.29%
iShares Micro-Cap ETF0.23%

OakChart. MNPR. Cached 15 minutes.